{"id":"f1db1229c69a","type":"article","url":"https://hartvaat.nl/2016/11/01/langetermijnmortaliteit-bij-hypertensie-met-coronairlijden-invest-us-cohort/","title":"Langetermijnmortaliteit bij hypertensie met coronairlijden: INVEST US-cohort","title_en":"Long-Term Mortality in Hypertensive Patients With Coronary Artery Disease: Results From the US Cohort of the International Verapamil (SR)/Trandolapril Study.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["bloeddrukbehandeling","farmaco-economie","sacubitril-valsartan"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.116.07854","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.116.07854","authors":["Islam Y Elgendy","Anthony A Bavry","Yan Gong","Eileen M Handberg","Rhonda M Cooper-DeHoff","Carl J Pepine"],"significance":6,"published":"2016-11-01","source_date":"2016-11-01","image":"","kennis":[],"congress":"","summary_en":"This long-term analysis of the US INVEST cohort showed that both excessively high and low achieved systolic blood pressure levels are associated with increased mortality in hypertensive coronary disease patients, informing the J-curve debate.","created":"2026-07-03T10:26:23Z","updated":"2026-07-03T18:38:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Langetermijnresultaten van het Amerikaanse INVEST-cohort naar mortaliteit bij hypertensieve patiënten met coronairlijden behandeld met verapamil versus atenolol.","abstract_original":"UNLABELLED: The dyad of hypertension and coronary artery disease is prevalent; however, data on systolic blood pressure (SBP) control and long-term all-cause mortality are lacking. Using extended follow-up data from the US cohort of the International Verapamil (SR)/Trandolapril Study (mean 11.6 years), subjects were categorized by age at enrollment (50 to <60 and ≥60 years). Cox proportional adjusted hazard ratios (HRs) were constructed for time to all-cause mortality according to achieved mean SBP. In those 50 to <60 years and using a referent SBP of <130 mm Hg, an achieved SBP of 130 to 140 mm Hg was associated with a similar risk of mortality (HR, 1.03; 95% confidence interval [CI], 0.87-1.23), whereas an achieved SBP of ≥140 mm Hg was associated with an increased risk of mortality (HR, 1.80; 95% CI, 1.53-2.11). Among subjects aged ≥60 years and using a referent SBP of <130 mm Hg, an achieved SBP 130 to 140 mm Hg was associated with a lower mortality risk (HR, 0.92; 95% CI, 0.85-0.98). There was an increased risk of mortality with an achieved SBP ≥150 mm Hg (HR, 1.34; 95% CI, 1.23-1.45), but not with an achieved SBP 140 to 150 mm Hg (HR, 1.02; 95% CI, 0.94-1.11). In hypertensive patients with coronary artery disease, achieving a SBP of 130 to 140 mm Hg seems to be associated with lower all-cause mortality after ≈11.6 years of follow-up. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00133692."}